Akebia Therapeutics, Inc.AKBANASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank62
3Y CAGR+68.8%
5Y CAGR+14.3%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+68.8%/yr
vs -38.1%/yr prior
5Y CAGR
+14.3%/yr
Recent acceleration
Acceleration
+106.9pp
Accelerating
Percentile
P62
Within normal range
vs 5Y Ago
2x
Strong expansion
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 1.89 | -43.8% |
| 2024 | 3.36 | +122.4% |
| 2023 | 1.51 | +284.6% |
| 2022 | 0.39 | -77.0% |
| 2021 | 1.71 | +76.5% |
| 2020 | 0.97 | -54.3% |
| 2019 | 2.12 | -21.0% |
| 2018 | 2.68 | -17.3% |
| 2017 | 3.24 | -97.6% |
| 2016 | 133.74 | - |